微量白蛋白尿和DR患者GFR下降最快。
Patients with microalbuminuria and DR showed the fastest GFR decline.
所以我们是在病人中观察新发生的微量白蛋白尿。
So we were looking at the developments of new microalbuminuria in these patients.
介绍了尿微量白蛋白的产生机理、临床意义以及分析进展。
The generation mechanism, clinical value and the analytical progress of microalbumin wre also reviewed.
结论微量白蛋白尿的测定可用于监测、防治糖尿病性心脏病。
Conclusions The menstruations of micro albumin urine can be applied to the prevention of diabetic heart disease.
目的了解肥胖症患儿尿微量白蛋白的改变及瘦素的致病作用。
Objective To understand change of microalbuminuria in adiposity and pathogenesis of leptin.
结论尿微量白蛋白测定是一种灵敏、简便、快速的测定方法。
Conclusion Microdose albumin detection is a sensitive, convenient and quick method which can be widely applied in the routine LABS.
体外循环前后血中可溶性细胞间粘附分子-1及尿微量白蛋白的变化。
Observation of the change of soluble intercellular adhesion molecules-1 and urea microalbumin during cardiopulmonary bypass.
微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
糖尿病患者尿中白蛋白水平增加，微量白蛋白尿是糖尿病肾病的早期表现。
An increased level of albumin in the urine of people with diabetes is an early sign of kidney damage.
目的研究高血压患者脉压与尿白蛋白排泄率及微量白蛋白尿阳性率的关系。
Objective: To investigate the relationship between pulse pressure (PP) and urinary albumin excretion(UAE) and microalbuminuria (Malb) in patients with essential hypertension.
目前正在进行观察性随访研究，以进一步了解预防微量白蛋白尿的长期益处。
An observational follow-up study is underway to further understand the long-term benefits of microalbuminuria prevention.
结果高血压和糖尿病组病人中尿微量白蛋白的变化和肾损伤的程度呈正相关性。
Results Positive correlation is expressed between the level of kidney trauma and the variation of microdose albumin in the high blood pressure group patients and diabetes group patients.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
目的探讨老年及高龄高血压患者尿微量白蛋白(mau)和大动脉僵硬度的关系。
Objective To explore the relationship between microalbuminuria (MAU) and stiffness of large artery in elderly and very elderly hypertensive patients.
目的观察在微量白蛋白尿发生前后应用氯沙坦对糖尿病肾病(DN)的治疗作用及其机制。
Objective To estimate the therapeutical effect and mechanism of losartan on diabetic nephropathy (DN) before and after microalbuminuria.
目的：研究急性脑梗死患者微量白蛋白尿的发生率、与脑卒中危险因素及脑梗死复发的关系。
OBJECTIVE: to investigate the relationship between the incidence of MAU in patients with acute cerebral infarction and the risk factor of stroke and the recurrence of cerebral infarction.
实验结果显示尿微量白蛋白降低76.2%，表明罗布麻提取物起到显著的保护肾功能作用。
The results showed 76.2% reduction of urinary albumin, indicating that Apocynum extracts play a significant protection of renal function.
此外，ROADMAP数据证明奥美沙坦可预防2型糖尿病患者发生微量白蛋白尿(mau)。
In addition, data from ROADMAP proved that olmesartan can reduce risk of microalbuminuria (MAU) in Type 2 diabetes (T2DM) patients.
目的探讨微量白蛋白尿(MA)与非糖尿病急性心肌梗死(NDM AMI)患者预后的关系。
Objective To investigate prognostic significance of microalbuminuria (MA) in non-diabetic acute myocardial infarction (NDM-AMI) patients.
结论中药护肾胶囊可明显减少尿微量白蛋白排泄率，改善高血脂、高血黏滞状态，保护肾功能。
Conclusion Hushen capsule could reduce notably excretory rate of urine trace albumin, which could improve the blood viscosity, hyperlipidemia and renal function.
目的研究急性脑梗死患者微量白蛋白尿(mau)的发生率、与卒中危险因素及脑梗死复发的关系。
Objective to assess the prevalence of microalbuminuria (MAU) in patients with recent cerebral infarction and its associations to risk factors for stroke and recurrence.
结果：依那普利治疗后尿微量白蛋白较治疗前明显减少（P<0.01）；空腹血糖与血压基本稳定。
Results:After using enalapril microdosis urinary albumin decreased obviously compared with that before treatment(P<0.01), while fasting blood glucose and blood pressure stabilized basically.
方法30例肥胖症患儿用免疫比浊法测定晨起尿微量白蛋白，同时测定血压、血糖、血脂、胰岛素、瘦素。
Methods Microalbuminuria was mensurated by immunoturbidmetric methods in 30 cases of adiposity in morning, meanwhile blood press, blood sugar, blood fat, blood insulin, blood leptin were mensurated.
对糖尿病组患者进行眼底、尿微量白蛋白、尿肌酐和颈动脉、股动脉、髂总动脉内中膜厚度（IMT）检查。
Eye fundus, urine microalbumin, urine creatinine and intima-media thickness(IMT) of carotid artery, femoral artery and common iliac artery were observed in diabetic group.
结论普伐他汀可改善代谢综合征患者的血脂紊乱、高血压及微量白蛋白尿，可安全地应用于代谢综合征患者。
Conclusion Pravastatin can be safely used for treating metabolic syndrome because it can ameliorate the lipid disturbance, hypertension and microalbuminuria.
本研究以糖尿病患者出现肾损害的最初临床表现——微量白蛋白尿的出现比率作为标准，进行各组间的比较。
Rates of microalbuminuria-small amounts of the protein albumin in urine, the first sign of diabetic kidney disease-were compared between groups.
微量白蛋白尿是糖尿病肾病发病的首要指征，也是早期出现心血管疾病的重要指征之一，可提示微血管病变。
Microalbuminuria is the first sign of the pathogenesis of diabetic nephropathy. It is also an important marker of early development of cardiovascular disease and can indicate microvascular disease.
多数糖尿病患者起病后6～15年开始出现微量白蛋白尿，10～15年后进入显性蛋白尿期，出现大量蛋白尿。
Most diabetic patients began to have microalbuminuria after 6 to 15 years when they were diagnosed diabetes, 10 to 15 years later they went into a period of large volume proteinuria.
至于微量白蛋白尿与胰岛素抵抗有直接的病理生理联系，还是仅与该综合征的某些代谢紊乱有关，目前尚不清楚。
It is still unclear whether microalbuminuria is directly associated with insulin resistance in pathophysiology or it is merely related...
应用推荐